Medical Market Report

Global IBS Treatment Market By Type (By Types, IBS-D, IBS-C, IBS-M, By Drugs Type, Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, and Alosetron), By Application (Hospitals, Clinics, and Research Laboratories), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 139031
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global IBS Treatment Market is estimated to be valued US$ XX.X million in 2019. The report on IBS Treatment Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global ibs treatment market is segmented on the basis of Type, Application, and geography.

    In 2019, the North America market is valued US$ XX.X million and the market share is estimated X.X%, and it is expected to be US$ XX.X million and X.X% in 2029, with a CAGR X.X% from 2020 to 2029.

    IBS Treatment Market Scope:

    By type, the market is segmented into By Types, IBS-D, IBS-C, IBS-M, By Drugs Type, Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, and Alosetron. By Application, the market is divided into Hospitals, Clinics, and Research Laboratories.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals Inc. (U.S.), Ardelyx Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), and Pfizer Inc (U.S.).

    Key Market Segments

    Type

    By Types

    IBS-D

    IBS-C

    IBS-M

    By Drugs Type

    Lubiprostone

    Linaclotide

    Eluxadoline

    Rifaximin

    Alosetron

    Application

    Hospitals

    Clinics

    Research Laboratories

    Key Market Players included in the report:

    Allergan Plc (Ireland)

    Sucampo Pharmaceuticals (U.S.)

    Ironwood Pharmaceuticals Inc. (U.S.)

    Astellas Pharma Inc. (Japan)

    Valeant Pharmaceuticals (Canada)

    Abbott Laboratories (U.S.)

    Synergy Pharmaceuticals Inc. (U.S.)

    Ardelyx Inc. (U.S.)

    Nestle (Switzerland)

    Sebela Pharmaceuticals (Ireland)

    Probi (Sweden)

    Alfasigma USA Inc. (Italy)

    RedHill Biopharma Ltd. (Israel)

    AstraZeneca (U.K)

    Ipsen (France)

    Novartis AG (Switzerland)

    Takeda Pharmaceutical Company Ltd (Japan)

    Synthetic Biologics Inc. (U.S.)

    Protagonist Therapeutics Inc. (U.S.)

    Pfizer Inc (U.S.)

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and IBS Treatment Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of IBS Treatment Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers IBS Treatment Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global IBS Treatment Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the IBS Treatment Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the IBS Treatment Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of IBS Treatment sub-markets, depending on key regions (various vital states).
    To analyze IBS Treatment Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the IBS Treatment Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide IBS Treatment Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. IBS Treatment Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope
    

    2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players
    

    3. Global IBS Treatment Market Overview
    

    3.1. IBS Treatment Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
    

      3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy
    

    4. Global IBS Treatment Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global IBS Treatment Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. By Types
    

      4.4. IBS-D
    

      4.5. IBS-C
    

      4.6. IBS-M
    

      4.7. By Drugs Type
    

      4.8. Lubiprostone
    

      4.9. Linaclotide
    

      4.10. Eluxadoline
    

      4.11. Rifaximin
    

      4.12. Alosetron
    

    5. Global IBS Treatment Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global IBS Treatment Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Hospitals
    

      5.4. Clinics
    

      5.5. Research Laboratories
    

    6. Global IBS Treatment Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America IBS Treatment Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe IBS Treatment Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific IBS Treatment Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America IBS Treatment Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa IBS Treatment Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    

    7. Global IBS Treatment Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Allergan Plc (Ireland)
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
    

      7.4. Sucampo Pharmaceuticals (U.S.)
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
    

      7.5. Ironwood Pharmaceuticals#Inc. (U.S.)
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
    

      7.6. Astellas Pharma Inc. (Japan)
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
    

      7.7. Valeant Pharmaceuticals (Canada)
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
    

      7.8. Abbott Laboratories (U.S.)
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
    

      7.9. Synergy Pharmaceuticals#Inc. (U.S.)
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
    

      7.10. Ardelyx#Inc. (U.S.)
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
    

      7.11. Nestle (Switzerland)
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
    

      7.12. Sebela Pharmaceuticals (Ireland)
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

      7.13. Probi (Sweden)
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
    

      7.14. Alfasigma USA#Inc. (Italy)
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments
    

      7.15. RedHill Biopharma Ltd. (Israel)
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments
    

      7.16. AstraZeneca (U.K)
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments
    

      7.17. Ipsen (France)
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments
    

      7.18. Novartis AG (Switzerland)
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments
    

      7.19. Takeda Pharmaceutical Company Ltd (Japan)
    

        7.19.1. Company Overview
    
    7.19.2. Financial Highlights
    
    7.19.3. Product Portfolio
    
    7.19.4. SWOT Analysis
    
    7.19.5. Key Strategies and Developments
    

      7.20. Synthetic Biologics#Inc. (U.S.)
    

        7.20.1. Company Overview
    
    7.20.2. Financial Highlights
    
    7.20.3. Product Portfolio
    
    7.20.4. SWOT Analysis
    
    7.20.5. Key Strategies and Developments
    

      7.21. Protagonist Therapeutics Inc. (U.S.)
    

        7.21.1. Company Overview
    
    7.21.2. Financial Highlights
    
    7.21.3. Product Portfolio
    
    7.21.4. SWOT Analysis
    
    7.21.5. Key Strategies and Developments
    

      7.22. Pfizer Inc (U.S.)
    

        7.22.1. Company Overview
    
    7.22.2. Financial Highlights
    
    7.22.3. Product Portfolio
    
    7.22.4. SWOT Analysis
    
    7.22.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.